Siemens Healthineers said Tuesday that the T¨¹V Rheinland certification agency has certified its first products under the new European In Vitro Diagnostic Regulation.

Illumina and Merck provided more details on Tuesday about their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination deficiency, or HRD, and identify best responders to PARP inhibitors.

Sinopharm Foreign Trade (Beijing) Co., Ltd., subsidiary of China National Pharmaceutical Group Corporation signed the agency agreement for the ¡°Immunocytochemical Detection Kit of p16/Ki-67¡± (hereinafter referred to as "p16/Ki-67¡±) with MXB Biotechnologies Co., Ltd., subsidiary of BSBE.

Consumer genetics testing and medical diagnostics pioneer DnaNudge today announces that it has signed a new major distributor agreement that will speed the commercial roll-out of its breakthrough rapid genetic testing solutions across Spain.

The proposed acquisition comes shortly after a court ordered Hill-Rom to complete its acquisition of Bardy Diagnostics, a cardiac monitoring specialist, for $375 million.

According to "Medical Device and Diagnostics Contract Research Organization Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type and Services and Geography", the market is expected to reach US$ 20,336.08 million in 2028 from US$ 12,314.65 million in 2021.

QIAGEN to join the DAX on September 20, 2021, the effective date for changes in index composition. QIAGEN to remain in TecDAX comprised of the 30 largest German technology sector companies.

Mindray has purchased 3,048,662 shares through the stock repurchase special securities account, accounting for 0.2508% of the total share capital of the company. The total amount paid is almost 1 Billon CNY.

China has announced plans to set up a third stock exchange to serve small and medium-sized businesses.

Digital health technology firm Cue Health is seeking up to $100 million in a proposed initial public offering, it said in a registration statement filed on Wednesday with the US Securities and Exchange Commission.

Belgian molecular diagnostics maker Biocartis on Thursday reported a 31 percent year-over-year increase in revenues for the first half of 2021 on strong sales of its Idylla system and related test cartridges.

August 20, the Hurun Research Institute in association with Jiaxing City in East China released the 2021 Hurun Global 500.

BioM¨¦rieux reported sales growth of 7 percent for the first half of 2021 compared to the first half of 2020.The Marcy l'Etoile, France-based diagnostics firm reported total sales of €1.57 billion ($1.86 billion) for the six-month period ended June 30, 2020, up from €1.48 billion for the first half of 2020.

Seegene said Wednesday that it has obtained CE marking for the use of its Combo Swab self-collection device with four of the firm's SARS-CoV-2 molecular diagnostic assays, enabling its use in the EU and other regions that accept the designation.

As of the end of August 2021, the first-half reports of IVD-related listed companies have basically been released. 64 IVD-related listed companies have achieved steady growth in the first half of 2021, and more than 70% of companies have shown positive growth in net profits.

The second quarter revenues of Burning Rock Biotech were up 19 percent year over year. The Chinese precision oncology firm recorded total revenues of RMB 127.3 million ($19.7 million) for the three months ended June 30, 2021, up from RMB 107 million for the same period in 2020.

The US Food and Drug Administration has granted 510(k) clearance and a CLIA waiver to a multiplex assay from Visby Medical to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The assay uses an instrument-free, single-use PCR device.

On August 17th, Autobio released a semi-annual performance report stating that the operating income was 1.678 billion yuan, an increase of 39.13% year-on-year; the net profit attributable to shareholders of listed companies was 413 million yuan, an increase of 50.63% year-on-year.

A federal jury on Friday ruled that Qiagen willfully infringed two patents owned by ArcherDx (now part of Invitae) and Massachusetts General Hospital and ruled that Qiagen must pay royalties and lost profits totaling about $4.7 million.

LumiraDx reduced the terms of the valuation for its SPAC merger from $5 billion to$3 billion citing a decline in COVID-19 testing